Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 98

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 98
---
 we are offering. An increase (decrease) of 100,000 in the number of Ordinary Shares offered by us would increase
(decrease) the net proceeds to us from this offering by $0.76 million, assuming no change in the assumed initial public offering
price and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

We currently expect to use
the net proceeds from this offering for the following purposes:

| ● | approximately $4.5 million for development activities (including the completion of our pivotal trial) and preparation of the PMA submission for GelrinC; |

| ● | approximately $1.0 million for operations (manufacturing, regulatory affairs and patents); |

| ● | approximately $0.5 million for research and development activities; |

| ● | approximately $0.5 million for EU marketing development (Medical Device Regulation qualification and scaleup); |

| ● | approximately $1.1                                                                                                       
 million for the repayment of the Bridge Loan, the loans under the 2024 Loan Agreements, the 2025 Loan Agreements and the 
 December 2024 Loan Agreement and accrued interest and applicable risk premium; and                                       |

| ● | $0.25 million to be paid to the Chairman of our board of directors in consideration of his services to the Company since 2019, for which he has not received compensation, which was approved by our 
 shareholders on March 20, 2025.                                                                                                                                                                      |

| ● | the remainder for working capital and general corporate 
 purposes and possible future acquisitions.              |

Although we currently anticipate
that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is
necessary. Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate
with certainty the exact amounts of the net proceeds from this offering that may be used for any of the above purposes on a stand-alone
basis. Amounts and timing of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization
efforts, regulatory approval and demand for our product candidates, operating costs and other factors described under “Risk Factors”
in this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will
not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds
from this offering. For additional information regarding the repayment